Bluebird bio CFO Transition
This article was originally published in Scrip
Executive Summary
Bluebird Bio, Inc., a company developing therapies for genetic diseases and cancer, has appointed Jeffrey Walsh chief financial and strategy officer – effective March 1, 2016. Current chief financial officer, Jim DeTore, has decided to leave the company – effective March 18, 2016. Since 2011 Walsh was chief operating officer at bluebird bio and prior to joining the company, he was chief business officer at Taligen Therapeutics. He has held senior business development, finance and operations roles at PathoGenesis Corp., AllScripts Healthcare Solutions, EXACT Sciences and Inotek Pharmaceuticals.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.